187 related articles for article (PubMed ID: 32867211)
21. Hematopoietic cytokines in the sera of patients with pancreatic cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Jurkowska G
Clin Chem Lab Med; 2005; 43(2):146-50. PubMed ID: 15843207
[TBL] [Abstract][Full Text] [Related]
22. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer.
Hua Y; Chen H; Wang L; Wang F; Wang P; Ning Z; Li Y; Liu L; Chen Z; Meng Z
Cancer Biomark; 2017 Jul; 20(1):95-100. PubMed ID: 28759959
[TBL] [Abstract][Full Text] [Related]
23. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
[TBL] [Abstract][Full Text] [Related]
24. CEA mRNA identification in peripheral blood is feasible for colorectal, but not for gastric or pancreatic cancer staging.
Piva MG; Navaglia F; Basso D; Fogar P; Roveroni G; Gallo N; Zambon CF; Pedrazzoli S; Plebani M
Oncology; 2000 Nov; 59(4):323-8. PubMed ID: 11096345
[TBL] [Abstract][Full Text] [Related]
25. Serum CXCL8 and Its Specific Receptor (CXCR2) in Gastric Cancer.
Pawluczuk E; Łukaszewicz-Zając M; Gryko M; Kulczyńska-Przybik A; Mroczko B
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680333
[TBL] [Abstract][Full Text] [Related]
26. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection.
Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB
BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929
[TBL] [Abstract][Full Text] [Related]
27. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.
Chen Y; Gao SG; Chen JM; Wang GP; Wang ZF; Zhou B; Jin CH; Yang YT; Feng XS
Cell Biochem Biophys; 2015 Apr; 71(3):1287-91. PubMed ID: 25486903
[TBL] [Abstract][Full Text] [Related]
28. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
[TBL] [Abstract][Full Text] [Related]
29. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
30. The evaluation of diagnostic value of the tumor markers: CCSA-2 and CEA in colorectal cancer.
Knychalski B; Lukieńczuk T
Pol Przegl Chir; 2012 Feb; 84(2):86-92. PubMed ID: 22487741
[TBL] [Abstract][Full Text] [Related]
31. Serum DJ-1 as a diagnostic marker and prognostic factor for pancreatic cancer.
He XY; Liu BY; Yao WY; Zhao XJ; Zheng Z; Li JF; Yu BQ; Yuan YZ
J Dig Dis; 2011 Apr; 12(2):131-7. PubMed ID: 21401899
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
[TBL] [Abstract][Full Text] [Related]
33. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma.
Maeda S; Kuboki S; Nojima H; Shimizu H; Yoshitomi H; Furukawa K; Miyazaki M; Ohtsuka M
Cytokine; 2017 Jul; 95():12-21. PubMed ID: 28214673
[TBL] [Abstract][Full Text] [Related]
34. CA 242 is a new tumor marker for pancreatic cancer.
Röthlin MA; Joller H; Largiadèr F
Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
[TBL] [Abstract][Full Text] [Related]
35. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
Haglund C; Lundin J; Kuusela P; Roberts PJ
Br J Cancer; 1994 Sep; 70(3):487-92. PubMed ID: 8080735
[TBL] [Abstract][Full Text] [Related]
36. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
37. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study.
Imaoka H; Mizuno N; Hara K; Hijioka S; Tajika M; Tanaka T; Ishihara M; Hirayama Y; Hieda N; Yoshida T; Okuno N; Shimizu Y; Niwa Y; Yamao K
Pancreatology; 2016; 16(5):859-64. PubMed ID: 27256641
[TBL] [Abstract][Full Text] [Related]
40. CXCR2 +1208 CT genotype may predict earlier clinical stage at diagnosis in patients with prostate cancer.
Franz JM; Portela P; Salim PH; Berger M; Fernando Jobim L; Roesler R; Jobim M; Schwartsmann G
Cytokine; 2017 Sep; 97():193-200. PubMed ID: 28668699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
